Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;45(6):2257-2263.
doi: 10.21873/anticanres.17600.

Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts

Affiliations

Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts

Yohei Asano et al. Anticancer Res. 2025 Jun.

Abstract

Background/aim: Recent studies have shown that ivermectin, developed as an anti-parasitic drug, has efficacy against several cancer types. Methionine restriction, including the use of recombinant methioninase (rMETase), has been developed to target methionine addiction, a fundamental hallmark of cancer, termed the Hoffman effect. Metastatic colorectal cancer (CRC) is a recalcitrant disease that requires novel and disruptive treatment approaches. The present study aimed to determine the efficacy of ivermectin in combination with rMETase on a CRC cell line compared to normal fibroblasts.

Materials and methods: The human CRC cell line HCT-116 and normal human fibroblasts Hs27 were seeded at a density of 1,000 cells per well in 96-well plates and cultured overnight at 37°C. After treatment with ivermectin (0.5 μM to 128 μM) or rMETase (0.0625 U/ml to 8 U/ml) for 72 h, cell viability was assessed using the WST-8 reagent to determine the half-maximal inhibitory concentration (IC50) values for ivermectin and rMETase on both cell lines. Using these IC50 values, cell-viability assays for ivermectin alone, rMETase alone, and the combination of ivermectin and rMETase were performed on both cell lines to determine their synergy.

Results: The IC50 value for ivermectin alone was 4.81 μM and rMETase alone was 0.61 U/ml against HCT-116 colon-cancer cells. The IC50 value for ivermectin alone was 8.67 μM and rMETase alone was 0.67 U/ml against Hs27 normal fibroblasts. In HCT-116 cells, treatment with the combination of ivermectin and rMETase resulted in greater reduction of cell proliferation, compared to treatment with each drug alone; however, no synergy was observed against Hs27 cells.

Conclusion: rMETase and ivermectin showed selective synergistic anti-cancer efficacy against colon-cancer cells, indicating the clinical potential of the combination for metastatic CRC.

Keywords: Hoffman effect; Ivermectin; colorectal cancer; combination; methionine addiction; normal fibroblasts; recombinant methioninase (rMETase); synergy.

PubMed Disclaimer

LinkOut - more resources